|
Hedrin® for the Treatment of Head Lice
Hedrin is a novel, non-insecticide, one hour treatment for pediculosis (head lice) and is currently being developed in the United States as a prescription medical device. Hedrin is the top selling head lice product in Europe. It is currently marketed in 32 countries and, according to Thornton & Ross Ltd. (“T&R”), achieved 2008 annual sales through its licensees of approximately $48 million (USD) at in-market public prices, garnering approximately 23% market share across Europe.
In February 2008, Manhattan Pharmaceuticals entered into a joint venture agreement with Nordic Biotech Advisors ApS to develop and commercialize Hedrin for the North American market. The Hedrin JV now owns, is developing, and is working to secure commercialization partners for Hedrin in both the United States and Canada.
According to the American Academy of Pediatrics an estimated 6-12 million Americans are infested with head lice each year, with pre-school and elementary children and their families affected most often.
Burgess I, Brown C, Lee P. Treatment of head louse infestation with 4% dimeticone lotion: randomized controlled equivalence trial. BMJ. 2005 Jun 18;330(7505):1423.
Burgess I, Lee P, Matlock G. Randomised, controlled, assessor blind trial comparing 4% dimeticone lotion with 0.5% malathion liquid for head louse infestation. PLoS ONE. 2007 Nov 7;2 (11):e1127
| Copyright © Manhattan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy. |